Stocktube video
13/02/2012

Immupharma CEO says its flagship product, Lupuzor, has great potential

View full size
Additional Information
Market: AIM
Sector: Pharmaceuticals & Biotechnology
EPIC: IMM
Latest Price: 63.50p  (-0.98% Descending)
52-week High: 100.00p
52-week Low: 57.00p
Market Cap: 51.77M
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Is IMM a Buy, Sell or Hold?Get your FREE analysis of IMM
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
ImmuPharma PLC
www.immupharma.com

ImmuPharma plc is a drug discovery and development company. The Company, along with its subsidiaries, is principally engaged in investing in pharmaceutical research and development companies. The Company has operations in Mulhouse, France and Basle, Switzerland. The ImmuPharma plc focuses to develop drugs to treat serious medical conditions. It has five drugs in development to treat: lupus, cancer, severe pain, highly resistant infections, such as methicillin-resistant staphylococcus aureus (MRSA) and inflammatory and allergic disorders. Its wholly owned subsidiaries include ImmuPharma (UK) Limited, which is a holding company; ImmuPharma (France) SA, which is engaged in pharmaceutical research and development, and ImmuPharma AG, which is engaged in pharmaceutical research and development.

Full ImmuPharma PLC profile here
All RNS Press Releases

RNS Release - Notification of Major Interest in Shares

8th Nov 2011, 11:43 am
RNS Number : 6925R
Immupharma PLC
08 November 2011
 



 




TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi



1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached: ii

Immupharma plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached


An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments


An event changing the breakdown of voting rights


Other (please specify):



3. Full name of person(s) subject to the
notification obligation: iii

Rhone Trustees (Switzerland) SA

4. Full name of shareholder(s)
 (if different from 3.):iv

Same as above

5. Date of the transaction and date on
which the threshold is crossed or
reached: v

4 November 2011

6. Date on which issuer notified:

7 November 2011

7. Threshold(s) that is/are crossed or
reached: vi, vii

4%



 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of
shares


if possible using
the ISIN CODE

Situation previous
to the triggering
transaction

Resulting situation after the triggering transaction

Number
of
Shares

Number
of
Voting
Rights

Number
of shares

Number of voting
rights

% of  voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary shares

3,111,000

3,111,000

3,386,000

3,386,000

0

4.15%


GB0033711010


B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial
instrument

Expiration
date xiii

Exercise/
Conversion Period xiv

Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.

% of voting
rights

N/A

N/A

N/A

N/A

N/A


C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial
instrument

Exercise price

Expiration date xvii

Exercise/
Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

N/A




 

 

Nominal

Delta




Total (A+B+C)

Number of voting rights

Percentage of voting rights

3,386,000

4.15%



 

9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable: xxi

N/A

 


Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will cease
to hold:

N/A

12. Date on which proxy holder will cease to hold
voting rights:

N/A



13. Additional information:

Rhone Trustees (Switzerland) SA has replaced Pictet Overseas Trust Corporation Ltd as trustee.

14. Contact name:

Tracy Weimar, Company Secretary

15. Contact telephone number:

020 7152 4080

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLLLFSLLLLTIIL

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.